Here's the Deal
 

Baird's Investment Banking Group is pleased to announce the following transaction:

August 2012


Exact Sciences Corporation
Follow-on Offering
$61.7 Million


Baird served as a joint bookrunner in this transaction


Exact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq: EXAS) recently completed a follow-on offering of 6,325,000 shares of its common stock at a price of $9.75 per share, generating gross proceeds of approximately $61.7 million. The Company intends to use the net proceeds from this offering for general corporate and working capital purposes, including for product development and in furtherance of the Company’s efforts to obtain FDA clearance of its sDNA colorectal cancer screening product and product commercialization activities.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

For additional information about this transaction, please contact:
Managing Director
(414) 765-7079
Director
(650) 858-3817
Vice President
(414) 765-3802

Social Icons

Careers|Help|Site Map|Important Disclosures|Privacy Policy|Financial Information|Business Continuity
©2013 Robert W. Baird & Co. Incorporated.
Global Websites: Europe | Asia
The services featured on this Web site may not be available in all jurisdictions or to all persons/entities. For more information, please see Important Disclosures. Robert W. Baird & Co. Incorporated. Member SIPC.